Kiniksa Pharmaceuticals Reports Strong Q2 Earnings and Raised Revenue Guidance
Kiniksa Pharmaceuticals International reported second-quarter revenue from its drug ARCALYST of $243.6 million, representing a 55% year-over-year increase driven by growth in new and repeat prescribers. The company raised its full-year 2026 revenue guidance to between $980 million and $995 million, up from the previous range of $930 million to $945 million. Kiniksa also announced progress on KPL-387, selecting a monthly dose of 300 milligrams based on Phase II results showing rapid treatment response. The pivotal Phase III PASTEURAL trial is now enrolling patients with an expected commercial launch in the 2028–2029 timeframe. Additionally, Kiniksa reported $27.2 million in operating income and ended Q2 with $525.9 million in cash. The company's direct-to-consumer campaign for ARCALYST reached thousands of patients, showing early engagement signs. Chief Operating Officer Ross Moat highlighted the success of commercial strategies including AI tools and targeted outreach.
Tickers: $KNSA